logo-loader
VentriPoint Diagnostics Ltd.

VentriPoint's VMS System used to test 500 Sarcoidosis patients in Netherlands

Ventripoint Diagnostics (CVE:VPT-OTCQB-VPTDF) CEO George Adams  joined Steve Darling from Proactive Investors Vancouver on Skype with news their VMS System was used to study patients with Sarcoidosis, an inflammatory disease that affects multiple organs in the body, including the heart.

Adams told Proactive how many patients where in the study and how the company will be using this data going forward. Adams also had an update on what the company will be doing in China in 2019.

Quick facts: VentriPoint Diagnostics Ltd.

Price: $0.12

Market: TSX-V
Market Cap: $6.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks flat as a pancake but CROP shares jump on first...

Cannabis stocks cruised into Friday flat as a pancake across North American markets. Buds today were CROP Infrastructure Corp (CSE:CROP) (OTCMKTS:CRXPF), True Leaf Brands Inc (CSE:MJ) (OTCMKTS:TRLFF), while the duds were TerrAscend Corp (CSE:TER) (OTCMKTS:TRSSF),...

7 hours, 37 minutes ago

2 min read